LEADER 03890oam  22007933u 450 
001 996594971603316
005 20230908161908.0
010   $a3-319-09665-6
024 7 $a10.1007/978-3-319-09665-0
035   $a(CKB)3710000000324926
035   $a(SSID)ssj0001407852
035   $a(PQKBManifestationID)11967298
035   $a(PQKBTitleCode)TC0001407852
035   $a(PQKBWorkID)11432052
035   $a(PQKB)11370949
035   $a(DE-He213)978-3-319-09665-0
035   $a(MiAaPQ)EBC3107122
035   $a(MiAaPQ)EBC6422866
035   $a(Au-PeEL)EBL6422866
035   $a(OCoLC)899508284
035   $a(PPN)183153286
035   $a(EXLCZ)993710000000324926
100   $a20141218d2015      u|         0
101 0 $aeng
135   $aurnn#---mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aHigh Density Lipoproteins $eFrom Biological Understanding to Clinical Exploitation /$fedited by Arnold von Eckardstein, Dimitris Kardassis
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (xiii, 694 pages) $ccolour illustrations; digital, PDF file(s)
225 1 $aHandbook of Experimental Pharmacology ;$v224
300   $aBibliographic Level Mode of Issuance: Monograph
311 08$aPrint version: 9783319096643 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aPreface -- Part 1. Physiology of HDL -- Part 2. Pathology of HDL -- Part 3. Possible Indications and Target Mechanisms of HDL Therapy -- Part 4. Treatments for Dyslipidemias and Dysfunction of HDL.
330   $aIn this Handbook of Experimental Pharmacology on ?High Density Lipoproteins ? from biological understanding to clinical exploitation? contributing authors (members of COST Action BM0904/HDLnet) summarize in more than 20 chapters our current knowledge on the structure, function, metabolism and regulation of HDL in health and several diseases as well as the status of past and ongoing attempts of therapeutic exploitation. The book is of interest to researchers in academia and industry focusing on lipoprotein metabolism, cardiovascular diseases and immunology as well as clinical pharmacologists, cardiologists, diabetologists, nephrologists and other clinicians interested in metabolic or inflammatory diseases.
410  0$aHandbook of Experimental Pharmacology ;$v224
606   $aPharmacology
606   $aMolecular biology
606   $aHuman physiology
606   $aImmunology
606   $aCell biology
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
606   $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X
606   $aHuman Physiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B13004
606   $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000
606   $aCell Biology$3https://scigraph.springernature.com/ontologies/product-market-codes/L16008
615  0$aPharmacology.
615  0$aMolecular biology.
615  0$aHuman physiology.
615  0$aImmunology.
615  0$aCell biology.
615 14$aPharmacology/Toxicology.
615 24$aMolecular Medicine.
615 24$aHuman Physiology.
615 24$aImmunology.
615 24$aCell Biology.
676   $a572.68
702   $aEckardstein$b Arnold von$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aKardassis$b Dimitris$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a996594971603316
996   $aHigh density lipoproteins$91102727
997   $aUNISA